P2Y12 (P2RY12) Human shRNA Lentiviral Particle (Locus ID 64805)

CAT#: TL302719V

P2RY12 - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, >10^7 TU/ml.

Product Images

GFP signal was observed under microscope at 48 hours after transduction of TL302719A virus into HEK293 cells. TL302719A virus was prepared using lenti-shRNA TL302719A and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL302719B virus into HEK293 cells. TL302719B virus was prepared using lenti-shRNA TL302719B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of TL302719B virus into HEK293 cells. TL302719B virus was prepared using lenti-shRNA TL302719B and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL302719C] virus into HEK293 cells. [TL302719C] virus was prepared using lenti-shRNA [TL302719C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL302719C] virus into HEK293 cells. [TL302719C] virus was prepared using lenti-shRNA [TL302719C] and TR30037 packaging kit.

• 

  GFP signal was observed under microscope at 48 hours after transduction of [TL302719D] virus into HEK293 cells. [TL302719D] virus was prepared using lenti-shRNA [TL302719D] and TR30037 packaging kit.

• GFP signal was observed under microscope at 48 hours after transduction of [TL302719D] virus into HEK293 cells. [TL302719D] virus was prepared using lenti-shRNA [TL302719D] and TR30037 packaging kit.

Show all 7 images

Specifications

Product Data

• Locus ID: 64805
• Synonyms: ADPG-R; BDPLT8; HORK3; P2T(AC); P2Y(12)R; P2Y(AC); P2Y(ADP); P2Y(cyc); P2Y12; SP1999
• Vector: pGFP-C-shLenti
• Format: Lentiviral particles
• RefSeq: NM_022788, NM_176876, NM_022788.1, NM_022788.2, NM_022788.3, NM_022788.4, NM_176876.1, NM_176876.2, BC017898, BC017898.1, BM926255, NM_176876.3
• UniProt ID: Q9H244
• Summary: The product of this gene belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is involved in platelet aggregation, and is a potential target for the treatment of thromboembolisms and other clotting disorders. Mutations in this gene are implicated in bleeding disorder, platelet type 8 (BDPLT8). Alternative splicing results in multiple transcript variants of this gene. [provided by RefSeq, Jul 2013]
• shRNA Design: These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.
• Performance Guaranteed: OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.
  
  For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).